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Drug-induced uveitis is an uncommon but important cause of ocular inflammation.
Uveitis can be seen in association with various systemic, topical, and intraocular
medications. In this article, we review commonmedications associated with uveitis. Most
cases of drug-induced uveitis resolve with termination of the suspected medication with
or without administration of topical or systemic steroids. It is important for clinicians to
readily identify medications that may cause uveitis in order to provide rapid treatment,
avoid consequences of longstanding inflammation, and prevent costly and excessive
laboratory testing.
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INTRODUCTION
Uveitis is generally defined as inflammation in
the uveal tract, which is composed of the iris,
ciliary body, and choroid. Uveitis most commonly
affects young, working-age adults, and it has
been reported to be responsible for 5–20% of
all cases of blindness in the United States and
worldwide.[1, 2] According to the International
Uveitis Study Group, uveitis is classified based
on anatomic location of involvement, and can
manifest as anterior, intermediate, posterior, and
panuveitis.[3–5] It can also be classified based on
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etiology, including infectious, non-infectious, and
masquerade syndromes.[3]
Medications are a rare cause of uveitis,
comprising <0.5% of cases.[1, 6] Drug-induced
uveitis, although uncommon, can sometimes cause
severe inflammation and is easily misdiagnosed.
Hence, a high degree of suspicion is required
to establish the diagnosis. Several criteria have
been proposed to describe the causality of
adverse events from medications, including
a reaction that is frequently described and
documented, recovery upon drug withdrawal,
more severe reaction with higher doses, and
recurrence with drug rechallenge; rarely does a
drug meet all of these criteria.[7] The pathogenesis
of drug-induced uveitis is not fully understood,
but various mechanisms have been proposed
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including a direct effect from topical application
or intracameral injection, metabolite effects
from drug detoxification, type III hypersensitivity
reaction with immune complex deposition of
antidrug antibodies, and antigens liberated
from drug-induced death of microorganisms.[8]
Medications may also be broken down into free
radicals that bind melanin in the uveal tract,
which can cause toxicity and reduce melanin’s
ability to scavenge other free radicals, causing
uveitis.[8, 9]
In the current article, we review common
systemic, topical, intracameral, and intravitreal
medications associated with uveitis. New
medications linked to uveitis that have been
reported in the literature will also be highlighted.
TOPICAL MEDICATIONS
Brimonidine
Brimonidine is an alpha-2 adrenergic agonist
that is administered topically to reduce
intraocular pressure. Acute granulomatous
or non-granulomatous anterior uveitis with an
elevated intraocular pressure has been reported
with brimonidine use.[10, 11] The mechanism by
which this inflammatory response occurs is largely
unknown, but there is a higher risk in patients with
history of allergic conjunctivitis from brimonidine
use and in patients using drops for >12 months.[12]
Stopping the medicine usually resolves the
inflammation and rechallenge results in recurrence
of uveitis.[11]
Prostaglandin analogues
Topical prostaglandin analogs increase
uveoscleral outflow of aqueous humor, and are
used in the treatment of glaucoma.[13] Latanoprost
is associated with a 5% risk of anterior uveitis
within the first several months of treatment.[14, 15]
A significant increase in anterior chamber cell
and flare has been reported at three and
six months after the initiation of latanoprost,
travoprost, and bimatoprost.[16] This may be due
to breakdown of the blood–aqueous barrier
and subsequent elevation of cytokines in the
anterior chamber.[16, 17] Use of these drops has also




Intracameral vancomycin is used for prevention
of endophthalmitis following cataract surgery.[18]
However, vancomycin use has been associated
with hemorrhagic occlusive retinal vasculitis
(HORV), often presenting with anterior chamber
and vitreous inflammation as well as painless vision
loss.[18] All reported cases of HORV presented
within 1–21 days (mean ∼8 days) after vancomycin
use. These patients received vancomycin via
intracameral injection, intravitreal injection, or
through the irrigation bottle. Retinal vasculitis in
most of these patients resulted in poor visual
outcomes.[18] The proposed mechanism by which
this reaction occurs is via a delayed immune
response to the drug itself.[18]
Anti-vascular endothelial growth factor (anti-
VEGF) agents
Anti-vascular endothelial growth factors (anti-
VEGFs) such as bevacizumab (Avastin®),
ranibizumab (Lucentis®), and aflibercept (Eylea®)
are commonly used in the treatment of neovascular
age-related macular degeneration, macular edema
secondary to diabetic retinopathy and vascular
occlusion, and proliferative retinopathies. After
two years of anti-VEGF therapy, there is a two-fold
increase in the prevalence of uveitis compared to
disease-matched controls.[19]
Intraocular inflammation has been the
dose-limiting variable for intravitreal use of
ranibizumab.[20] During the FOCUS trial, a 12%
rate of uveitis was found following ranibizumab
injection; however, the majority of these cases
occurred prior to switching from the lyophilized
formulation (no longer in use) to the liquid
formulation, as well as prolonging the interval
between injection and verteporfin photodynamic
therapy.[21] These changes were made to the
protocol due to concerns that these factors
increased the risk of uveitis.[21] ANCHOR and
MARINA clinical trials estimated that approximately
2% of patients receiving intravitreal injections of
ranibizumab developed significant inflammation
(classified as 3+ or more cell in the anterior
chamber) within three weeks of injection.[21, 22]
The HORIZON extension study evaluated the
long-term safety of ranibizumab in patients
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who had completed the ANCHOR, MARINA,
or FOCUS trials, and found that significant
intraocular inflammation presented in 1.7–
2.6% of the eyes receiving ranibizumab for
one to three years.[23] Another study reported
that both bevacizumab and aflibercept were
associated with a <1% risk of significant intraocular
inflammation.[24]
The newest drug in the anti-VEGF family
is Brolucizumab (Beovu®), which comprises a
humanized single-chain antibody fragment with a
molecular weight of 26kDa, and recently received
FDA approval for use in patients with wet age-
related macular degeneration.[25] The efficacy
and safety of brolucizumab was evaluated and
compared with aflibercept in the HAWK and
HARRIER phase-three multicenter randomized
trials, which found that uveitis was present in
2.2% and 0% of patients taking brolucizumab and
aflibercept, respectively.[25] About 90% of these
cases were mild to moderate, and were treated
successfully with topical corticosteroids.[25] In the
post-hoc analysis of the HAWK and HARRIER data,
Mones et al[26] reported that the incidence of
intraocular inflammation was 4.6% in eyes treated
with brolucizumab; 3.3% of patients developed
retinal vasculitis with occlusive vasculitis in 2.1%
of the eyes.[26] In addition, 0.7% of the cases
experienced at least moderate vision loss
(≥15 ETDRS letters), and most of these events
occurred in the first six months of drug use.
In the same study, the incidence of intraocular
inflammation in aflibercept-treated eyes was 1.1%,
with at least moderate vision loss in 0.14%.[26]
The mechanism for intraocular inflammation
secondary to anti-VEGF injections is not fully
understood, but some experts suggest that it
is due to the formation of anti-drug antibodies
and subsequent hypersensitivity reactions to the
medicine.[27]
Triamcinolone acetonide
Intravitreal injection of triamcinolone acetonide,
used in the treatment of non-infectious uveitis and
macular edema, has been associated with sterile
inflammation and non-infectious endophthalmitis.
The reported incidence is between 0.5% and 9.7%




Cidofovir is a nucleotide analog that inhibits
viral DNA polymerase and is used for the
treatment of infection with herpesviruses such
as cytomegalovirus (CMV).[28] Uveitis has been
reported in 25–50% of patients after a median
of 11 weekly doses of intravenous cidofovir.[29–32]
Uveitis is more common after intravitreal use of
cidofovir.[31] HIV patients who receive cidofovir for
CMV retinitis are at higher risk of uveitis. In these
patients, treatment with highly active anti-retroviral
therapy (HAART) is an independent risk factor,
likely secondary to higher circulating levels of
cidofovir in setting of HAART.[33] Moreover, it has
been suggested that an elevated level of CD4+
T-cells in HIV+ patients is a risk factor for cidofovir
uveitis, which makes it difficult to differentiate from
immune recovery uveitis.[33, 34] Concurrent use of
probenecid, on the other hand, can significantly
decrease the rate of ocular side effects as it
minimizes intraocular secretion of cidofovir.[35]
Cidofovir-induced hypotony is seen in 10–20% of
HIV+ patients treated for CMV retinitis.[31, 32] The
inflammation and hypotony usually respond to
treatment with topical steroids and cycloplegic
agents, but hypotony can persist for a long period
of time.[30, 35, 36]
Rifabutin
Rifabutin, used for prevention and treatment
of Mycobacterium avium complex (MAC) in
immunocompromised patients, can cause
unilateral or bilateral anterior uveitis (usually
associated with hypopyon), intermediate uveitis,
posterior uveitis, or retinal vasculitis.[14, 37] Uveitis
is usually dose-dependent and commonly
occurs between two weeks and seven months
following the initiation of therapy.[38] Serum
concentration and hence risk of inflammation
increases with concurrent use of antifungal azoles,
azithromycin, ethambutol, and some protease
inhibitors through inhibition of hepatic cytochrome
P450 enzymes.[28, 37] Notably, rifabutin-induced
uveitis has also been reported in children and
immunocompetent patients.[28] Inflammation
usually resolves with topical steroids.[28]
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Fluoroquinolones
Fluoroquinolones, which disrupt bacterial DNA
synthesis by inhibiting DNA gyrase and DNA
topoisomerase IV, have a broad spectrum of
antibacterial activity indicated for the treatment of
community-acquired pneumonia, sinusitis, chronic
bronchitis, intra-abdominal abscesses, and skin
infections.[39, 40] In Hinkle et al’s retrospective
analysis of 40 case reports of fluoroquinolone-
induced uveitis, moxifloxacin was associated
with 25 cases, but ofloxacin, ciprofloxacin,
levofloxacin, norfloxacin, and gatifloxacin have
also been reported to cause uveitis.[1, 28, 40, 41]
The mean onset of uveitis is 13 days after the
initiation of the drug (range: 0–20 days) and
is usually bilateral; three characteristic findings
in these patients include pigment dispersion
with pigmented keratic precipitates and high
intraocular pressure, diffuse iris transilluminating
defects, and atonic pupils.[40–42] Fluoroquinolone-
induced uveitis is more common in women
and has been associated with HLA-B27 and
HLA-B51 haplotypes, suggesting a possible
autoimmune predisposition.[40] Uveitis is treated
by discontinuing the drug and administration of
topical corticosteroids.[41]
Bisphosphonates
Bisphosphonates, pyrophosphate analogs that
inhibit osteoclast activity, are commonly used
to inhibit bone resorption in osteoporosis
and metastasis to bone.[28] They are strongly
associated with anterior uveitis, scleritis,
and episcleritis, with onset as early as 6 hr
after intravenous administration.[1, 43, 44] In a
large retrospective pharmacovigilance study,
zoledronate caused 51% of bisphosphonate-
induced uveitis, with alendronate and pamidronate
causing 23% and 13%, respectively.[1] The
bisphosphonates promote the release of
inflammatory cytokines such as interleukin
1, interleukin 6, and tumor necrosis factor
(TNF)-α, which can target the uveal tract.[45]
Resolution typically requires topical steroids and
discontinuation of the medicine.[28]
TNF-𝛼 Inhibitors
TNF-α inhibitors are a group of anti-inflammatory
biologics that are used for the treatment of
rheumatologic diseases such as rheumatoid
arthritis, psoriasis, and inflammatory bowel
disease, as well as scleritis and uveitis.[41] Five
anti-TNF- α drugs are currently approved for
the use in autoimmune diseases, including four
monoclonal antibodies (infliximab, adalimumab,
golimumab, and certolizumab) and a soluble
receptor blocker (etanercept).[46] All of these
medications have been paradoxically associated
with the development of anterior uveitis and
chorioretinitis. Inflammation is more common
with etanercept but has also been reported
with infliximab and adalimumab.[47] The onset of
uveitis is usually three weeks to six years after
starting the therapy.[41, 47, 48] Sarcoidosis has also
been reported in patients using etanercept.[46]
The etiology of anti-TNF-α-induced uveitis is
not fully understood, but it is hypothesized that
decreased TNF-α levels leads to higher interferon
levels and cytokine imbalances, resulting in auto-
antibody formation and increased inflammation.[49]
Treatment involves discontinuation of the drug,
with severe cases requiring systemic steroids[41]
[Figure 1].
Immune Checkpoint Inhibitors
Immune Checkpoint Inhibitors (ICIs) are emerging
cancer immunotherapies used in metastatic
melanoma and solid tumors.[1] They upregulate
the immune system by blocking immune
checkpoints that are regulators of immune
system, thus leading to activation of T-cells
and an immune response to tumor cells.[50, 51]
The different types of ICIs approved for use
in cancer patients include a CTLA-4 inhibitor
(ipilimumab), programmed cell death protein
1 (PD-1) inhibitors (pembrolizumab, nivolumab,
and cemiplimab), and PD-1 ligand inhibitors
(atezolizumab, avelumab, and durvalumab).[14, 52]
These medications have recently been linked
to ocular inflammation. Uveitis is seen in 1%
of patients and is usually bilateral with onset
between one and six months after the initiation
of treatment.[14, 51, 53, 54] There are also reports of
Vogt-Koyanagi-Harada (VKH) syndrome in patients
receiving ICIs.[1] Ocular inflammation in these
patients is managed with topical or periocular
steroids, but severe cases require systemic
steroids and discontinuation of ICIs[51] [Figure
2].
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Figure 1. Fluorescein angiography of a 67-year-old female with history of rheumatoid arthritis treated with etanercept who
developed uveitis and retinal vasculitis three months after the initiation of etanercept. Etanercept was discontinued and infliximab
was started which resulted in resolution of ocular inflammation.
Protein Kinase Inhibitors
Dysregulations in mitogen-activated protein
kinase (MAPK) signaling pathways and BRAF
gene mutations, seen in 50% of skin melanoma
patients, can cause cell proliferation and cancer
formation.[14] BRAF inhibitors, such as vemurafenib
and dabrafenib, and mitogen-activated protein
kinases (MEK) inhibitors, such as trametinib, are
new drugs of interest in the treatment of metastatic
cutaneous melanomas. These medications have
recently been linked to ocular inflammation.[1]
Uveitis usually occurs between six weeks and
eight months after the initiation of treatment,
and can present as anterior, intermediate,
posterior, or panuveitis; resolution typically
involves topical steroids.[14] There are also
reports of drug-induced VKH syndrome linked




There are reports of uveitis in association with
BCG, influenza, hepatitis B, varicella, and human
papilloma virus vaccines.[14] Most of these cases
respond to topical steroid treatment or observation
and permanent vision loss is rare.[14]
Other medications
Sulfonamides, including antibiotics (most
commonly trimethoprim-sulfamethoxazole),
diuretics, and sulfonylureas, have been associated
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Figure 2. (A) 77-year-old man with history of malignant skin melanoma treated with nivolumab presented with blurry vision in both
eyes. External exam showed poliosis of the eyelashes. Ultrawide field fluorescein angiography showed optic nerve and vascular
leakage (B) which improved after intravitreal injection of triamcinolone acetonide.
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Figure 3. Inflamed, indurated skin tattoos in a young patient with tattoo uveitis.
with bilateral anterior uveitis usually within a week
of drug initiation.[28, 41, 55] Topical metipranolol, a
nonselective β-blocker used to treat glaucoma, has
been linked to granulomatous anterior uveitis most
commonly when used at a higher concentration of
0.6%.[28, 56] Onset ranged from 2 to 31 months, and
strong dechallenge and rechallenge data have
also been reported.[41, 56] Other medications that
can rarely cause uveitis include podophyllum,
capsaicin, betaxolol, oral contraceptives,
diethylcarbamazine, corticosteroids, quinidine,
topiramate, and tuberculin skin tests.[6, 8, 14, 28]
Almost all of these cases resolved with cessation
of the medication and initiation of topical
steroids.[6, 14, 28]
Tattoo ink
There are multiple reports of patients with
simultaneous bilateral uveitis and elevated
inflamed skin tattoos. Skin biopsies from the
indurated tattoos in these patients revealed
granulomatous inflammation surrounding tattoo
pigments, and some patients developed non-
caseating granulomas in the draining lymph nodes
corresponding to the location of the tattoos.[57]
An association between systemic sarcoidosis
and tattoo uveitis has been reported by some
authors, but uveitis can be found with or without a
sarcoidosis diagnosis.[57, 58] Inflammation is more
commonly seen in association with black ink,
and there are reports of resolution of uveitis after
removal of the skin tattoos.[58] The etiology has
not been clearly defined, but a type IV delayed
hypersensitivity reaction has been proposed[58]
[Figure 3].
CONCLUSION
Drug-induced uveitis is seen in association with
a growing list of various topical, intraocular, and
systemic medications. Although uncommon,
medication-induced uveitis can cause severe,
vision-threatening inflammation, and will increase
in frequency with the development of new
medications. The diagnosis is often made by
a thorough history and evaluation of medication
list, and after ruling out other potential infectious
or non-infectious etiologies of ocular inflammation.
Early identification of uveitis and rapid treatment
can lead to decreasedmorbidity and complications
of longstanding uveal inflammation, thus improving
visual outcomes. Most of these cases respond to
cessation of the insulting agent in conjunction with
topical and/or systemic corticosteroids.[14]
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